Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Resmed (RSMDF) Research & Development (2016 - 2025)

Historic Research & Development for Resmed (RSMDF) over the last 17 years, with Q4 2025 value amounting to $91.0 million.

  • Resmed's Research & Development rose 1179.4% to $91.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $348.7 million, marking a year-over-year increase of 936.2%. This contributed to the annual value of $331.3 million for FY2025, which is 772.59% up from last year.
  • Per Resmed's latest filing, its Research & Development stood at $91.0 million for Q4 2025, which was up 1179.4% from $87.3 million recorded in Q3 2025.
  • Over the past 5 years, Resmed's Research & Development peaked at $91.0 million during Q4 2025, and registered a low of $55.9 million during Q1 2021.
  • Its 5-year average for Research & Development is $73.7 million, with a median of $76.1 million in 2023.
  • Its Research & Development has fluctuated over the past 5 years, first surged by 2149.82% in 2023, then surged by 83.47% in 2024.
  • Over the past 5 years, Resmed's Research & Development (Quarter) stood at $62.5 million in 2021, then rose by 11.79% to $69.9 million in 2022, then increased by 5.73% to $73.9 million in 2023, then increased by 10.14% to $81.4 million in 2024, then rose by 11.79% to $91.0 million in 2025.
  • Its Research & Development stands at $91.0 million for Q4 2025, versus $87.3 million for Q3 2025 and $86.4 million for Q2 2025.